The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | COMMODORE: gilteritinib for the treatment of R/R FLT3-mutated AML
Jianxiang Wang, MD, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, discusses the Phase III, open-label, multicenter COMMODORE (NCT03182244) trial, in which the safety and efficacy of gilteritinib was compared to salvage chemotherapy (SC) for the treatment of relapsed/refractory FLT3-mutated acute myeloid leukemia (R/R FLT3-mutated AML) across 234 randomised patients. Dr Wang describes how the primary endpoint, overall survival (OS), was found to be significantly longer for the gilteritinib arm compared to the SC control arm. A key secondary endpoint, event-free survival (EFS), was also found to be longer in patients receiving gilteritinib compared to those receiving SC. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Advisor of AbbVie
